A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Pulmaquin in the Management of Chronic Lung Infections With Pseudomonas Aeruginosa in Patients With Non-Cystic Fibrosis Bronchiectasis, Including 28 Day Open-Label Extension

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Pulmaquin in the Management of Chronic Lung Infections With Pseudomonas Aeruginosa in Patients With Non-Cystic Fibrosis Bronchiectasis, Including 28 Day Open-Label Extension

Completed
Phase of Trial: Phase III

Latest Information Update: 23 May 2018

At a glance

  • Drugs Ciprofloxacin (Primary)
  • Indications Bronchiectasis; Pseudomonal infections
  • Focus Registrational; Therapeutic Use
  • Acronyms ORBIT-4
  • Sponsors Aradigm Corporation
  • Most Recent Events

    • 23 May 2018 Results assessing the impact of ARD-3150 on subsequent occurrences of PE in ORBIT-3 and ORBIT-4 trials, presented at the 114th International Conference of the American Thoracic Society
    • 23 May 2018 Pooled results assessing safety and tolerability in ORBIT-3 and ORBIT-4 trials (n=582) presented at the 114th International Conference of the American Thoracic Society
    • 23 May 2018 Results assessing the effect of Ciprofloxacin on Severe Pulmonary Exacerbations in ORBIT-3 and ORBIT-4 trials, presented at the 114th International Conference of the American Thoracic Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top